From: Can incontinence be cured? A systematic review of cure rates
Follow-up | 3Â m | 6Â m | 12Â m | 18Â m | 2 y | 3 y | 5 y |
---|---|---|---|---|---|---|---|
Treatment – WOMEN | |||||||
TVT | 78% | 50% | 53%; 90.1%Â W | Â | Â | 89.5% | 81%Â W |
92% | |||||||
TVT-O | Â | Â | 82.3%; 94.1%; 92.3%; 76%; 88.4%Â W; 88.8% | Â | 92.6% | 86.4%; 87% 72% | 74% |
TVT Surgery/Individually tailored/MiniTape/SPARC | 83.1% W (Primus) | 27.7%Â W (North) | 85%; 82% (VL) | Â | 31.6%Â W (North) | Â | Â |
82.3%Â W (Primus) | 32.3%Â W (North) | ||||||
84.4%Â W (Primus) | |||||||
TOT | 82.8% | 84.3% | 63.4%; 74%; 88.6%; 93.3% | Â | Â | 65% | Â |
Retropubic TVT | Â | 89.7% | 86.1%; 65.5%; 81% | 80.1% | 77.4% | Â | Â |
Sling | 94.1% | 92.2%Â W; 81.3% | 81.2%; 90.8%; 90.1%Â W; 63.7%; 90.2%; 92.2%; 41% | 52.8% | 83.7%; 50.5% | Â | Â |
89.8%; 81%; 44% | |||||||
Colposuspension | Â | 22%/32% | Â | Â | Â | Â | 90%Â W |
28%/36% | |||||||
Other (surgery) | Â | Â | 79% | Â | Â | Â | Â |
PFMT – supervised | 52.9%; 5% |  | 58.8% |  |  |  |  |
Vaginal cone therapy | 9% | Â | Â | Â | Â | Â | Â |
Lifestyle advice – unsupervised | 8% |  |  |  |  |  |  |
Injectable bulking agents | Â | Â | 36.9%; 24.8% | Â | Â | Â | Â |
Duloxetine | NR | Â | Â | Â | Â | Â | Â |
Treatment – MEN | |||||||
Male sling | 80% | 55.8%Â W | 58%Â W; 51.4%Â W; 53.8% | 42.5% | 48%Â W; 54%Â W | 40%Â W; 53% | Â |
PFMT – supervised | 51.9% | 78% |  |  |  |  |  |
PFMT – unsupervised |  |  | NR |  |  |  |  |
PFMT – supervised + drug | 78% | 62% |  |  |  |  |  |